pre-IPO PHARMA

COMPANY OVERVIEW

Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best-in-class therapeutic antibodies with significant clinical and commercial differentiation.


LOCATION

  • La Jolla, CA, USA

  • THERAPEUTIC AREAS

  • Fibrotic DIsease
  • Inflammatory Disease
  • Metabolic Disorders

  • WEBSITE

    https://www.birdrockbio.com


    CAREER WEBSITE

    https://www.birdrockbio.com/careers/join-our-team/


    SOCIAL MEDIA


    INVESTORS

    5am-ventures apposite-capital aravis-sa m-ventures sr-one versant-ventures


    PRESS RELEASES


    May 28, 2020

    Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases


    Oct 17, 2019

    Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease


    Sep 13, 2018

    Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease


    Jun 5, 2017

    Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial for Namacizumab; Generates Safety, Tolerability, and Pharmacokinetics Data; Prepares To Initiate Study in Non-Alcoholic Fatty Liver Disease Patients


    Jan 11, 2017

    Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material, and Enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.


    For More Press Releases


    Google Analytics Alternative